English
Back
Open Account
港股窩輪Jenny
wrote a column · Jan 27 15:08

[Warrant Perspective] CSPC Pharma Challenges Short-term Resistance, How to Choose Derivatives

Hong Kong stock information on January 27, as of 13:47, shows that CSPC Pharma (01093) has strengthened following the recovery of the pharmaceutical sector. As a leading innovator in China's pharmaceutical industry, the company continues to release positive fundamentals. Progress on its self-developed Prulifloxacin tablets with new indications is proceeding smoothly, and its ADC drug SYSA1801 has been licensed for overseas development, potentially becoming a new growth engine. Coupled with stable supply from generic drug procurement, earnings growth certainty is strong. Technically, it presents a 'buy signal coexisting with overbought pressure' pattern, with a slightly optimistic upward probability of 52%. Stochastic oscillators issue a buy signal, while the VR trading ratio, bull-bear power index, MACD, and Bollinger Bands all indicate buying, showing sufficient underlying support. However, the RSI indicator at 66 is nearing the overbought zone, with multiple oscillators maintaining neutrality. In the short term, profit-taking pressures must be watched closely, focusing on the breakthrough strength at the resistance level of HK$10.15, while holding the support level at HK$9.26.
Analyzing support and resistance levels, CSPC Pharma's current price of HK$9.97 is only HK$0.18 away from the first resistance level at HK$10.15. This position represents a recent high point in volatility, and a breakout requires continuously increasing volumes supported by innovative drug benefits. If it successfully breaks through HK$10.15, the market outlook can aim for the second resistance level at HK$10.6. Conversely, if overbought pressure triggers a pullback, attention should focus on the defensive strength at the first support level of HK$9.26, which is close to the strong support areas of MA10 (HK$9.78) and MA30 (HK$8.94), backed by favorable policies supporting the pharmaceutical sector, indicating strong capital inflow. Even if it unexpectedly falls below this, the second support level at HK$8.78 also represents a key consolidation platform previously, offering substantial safety cushion as a solid innovation-driven pharmaceutical leader. Overall, the current stock price movement tightly correlates with 'progress in the innovative drug pipeline and stability in procurement supply.' The strength of the HK$9.26 support level determines short-term stability, while the HK$10.15 resistance level tests whether positive catalysts can drive the share price higher.
Hong Kong stock information on January 27, as of 13:47, shows that CSPC Pharma (01093) has strengthened following the recovery of the pharmaceutical sector. As a leading innovator in China's pharmaceutical industry, the company continues to release positive fundamentals. Progress on its self-developed Prulifloxacin tablets with new indications is proceeding smoothly, and its ADC drug SYSA1801 has been licensed for overseas development, potentially becoming a new growth engine. Coupled with stable supply from generic drug procurement, earnings growth certainty is strong. Technically, it presents a 'buy signal coexisting with overbought pressure' pattern, with a slightly optimistic upward probability of 52%. Stochastic oscillators issue a buy signal, while the VR trading ratio, bull-bear power index, MACD, and Bollinger Bands all indicate buying, showing sufficient underlying support. However, the RSI indicator at 66 is nearing the overbought zone, with multiple oscillators maintaining neutrality. In the short term, profit-taking pressures must be watched closely, focusing on the breakthrough strength at the resistance level of HK$10.15, while holding the support level at HK$9.26. Analyzing support and resistance levels, CSPC Pharma's current price of HK$9.97 is only HK$0.18 away from the first resistance level at HK$10.15. This position represents a recent high point in volatility, and a breakout requires continuously increasing volumes supported by innovative drug benefits. If it successfully breaks through HK$10.15, the market outlook can aim for the second resistance level at HK$10.6. Conversely, if overbought pressure triggers a pullback, attention should focus on the defensive strength at the first support level of HK$9.26, which is close to the strong support areas of MA10 (HK$9.78)...
The product review data fully confirms the 'profit potential of inverse-leveraged products during pharmaceutical leader volatility.' On January 22, when CSPC Pharma was in an adjustment phase, the stock dropped only 0.83% over three days, but UBS Bear Certificate 56938 achieved a 5% increase leveraging its high leverage advantage, perfectly capturing short-term volatility opportunities, demonstrating the flexibility of leveraged products amidst pharmaceutical sector fluctuations. Especially given CSPC Pharma's exposure to innovative drug policies, clinical progress, procurement results, etc., short-term volatility rhythm is clear, and mid-term benefits from overseas expansion of innovative drugs and a diversified product portfolio make it a preferred target for investors looking to capitalize on pharmaceutical sector trends.
Hong Kong stock information on January 27, as of 13:47, shows that CSPC Pharma (01093) has strengthened following the recovery of the pharmaceutical sector. As a leading innovator in China's pharmaceutical industry, the company continues to release positive fundamentals. Progress on its self-developed Prulifloxacin tablets with new indications is proceeding smoothly, and its ADC drug SYSA1801 has been licensed for overseas development, potentially becoming a new growth engine. Coupled with stable supply from generic drug procurement, earnings growth certainty is strong. Technically, it presents a 'buy signal coexisting with overbought pressure' pattern, with a slightly optimistic upward probability of 52%. Stochastic oscillators issue a buy signal, while the VR trading ratio, bull-bear power index, MACD, and Bollinger Bands all indicate buying, showing sufficient underlying support. However, the RSI indicator at 66 is nearing the overbought zone, with multiple oscillators maintaining neutrality. In the short term, profit-taking pressures must be watched closely, focusing on the breakthrough strength at the resistance level of HK$10.15, while holding the support level at HK$9.26. Analyzing support and resistance levels, CSPC Pharma's current price of HK$9.97 is only HK$0.18 away from the first resistance level at HK$10.15. This position represents a recent high point in volatility, and a breakout requires continuously increasing volumes supported by innovative drug benefits. If it successfully breaks through HK$10.15, the market outlook can aim for the second resistance level at HK$10.6. Conversely, if overbought pressure triggers a pullback, attention should focus on the defensive strength at the first support level of HK$9.26, which is close to the strong support areas of MA10 (HK$9.78)...
If you are optimistic about CSPC Pharma breaking through the HK$10.15 resistance level due to innovative drug benefits, focus on two call warrants and two bull certificates suitable for different risk appetites. Regarding call warrants, Huatai Call Warrant 17343 offers 7.4x leverage with a strike price of HK$10.93. Its features include 'lowest premium, relatively ideal implied volatility, and leverage,' meaning slower cost erosion and effective amplification of breakout gains via 7.4x leverage, making it suitable for aggressive investors seeking high elasticity; Bank of China Call Warrant 17640 offers 4.7x leverage with a strike price of HK$10.95. It has 'relatively lower implied volatility,' resulting in slower time decay, providing ample time even if a quick breakout doesn't occur, suitable for conservative players with strict cost control requirements. Regarding bull certificates, Societe Generale Bull Certificate 55818 and UBS Bull Certificate 56105... $UB#CSPC RC2711L.C (56105.HK)$ Both bull certificates have a stop-loss price at HK$9, well below the first support level at HK$9.26, providing ample safety margin even in case of a short-term deep pullback without triggering a stop-loss easily. The Societe Generale bull certificate offers actual leverage of 8x, featuring 'highest actual leverage and lower premium,' suitable for investors who want flexible position adjustments; the UBS bull certificate offers actual leverage of 8x, with 'highest actual leverage and lowest premium,' highlighting cost advantages, suitable for investors seeking steady swing profits.
If you are concerned about short-term corrections due to overbought pressure, consider UBS Bear Certificate 56938 $UB#CSPC RP2708A.P (56938.HK)$Bear warrants are the first choice for defense, with an actual leverage of 9.1 times and a stop-loss price of HK$10.5. They offer 'the highest actual leverage' and a stop-loss price above the resistance level of HK$10.15, providing sufficient safety margin. Even if the underlying stock slightly rises and breaks through HK$10.15, it is unlikely to trigger a stop-loss. Suitable for aggressive investors who are cautious about short-term trends and want to capture pullback opportunities.
Hong Kong stock information on January 27, as of 13:47, shows that CSPC Pharma (01093) has strengthened following the recovery of the pharmaceutical sector. As a leading innovator in China's pharmaceutical industry, the company continues to release positive fundamentals. Progress on its self-developed Prulifloxacin tablets with new indications is proceeding smoothly, and its ADC drug SYSA1801 has been licensed for overseas development, potentially becoming a new growth engine. Coupled with stable supply from generic drug procurement, earnings growth certainty is strong. Technically, it presents a 'buy signal coexisting with overbought pressure' pattern, with a slightly optimistic upward probability of 52%. Stochastic oscillators issue a buy signal, while the VR trading ratio, bull-bear power index, MACD, and Bollinger Bands all indicate buying, showing sufficient underlying support. However, the RSI indicator at 66 is nearing the overbought zone, with multiple oscillators maintaining neutrality. In the short term, profit-taking pressures must be watched closely, focusing on the breakthrough strength at the resistance level of HK$10.15, while holding the support level at HK$9.26. Analyzing support and resistance levels, CSPC Pharma's current price of HK$9.97 is only HK$0.18 away from the first resistance level at HK$10.15. This position represents a recent high point in volatility, and a breakout requires continuously increasing volumes supported by innovative drug benefits. If it successfully breaks through HK$10.15, the market outlook can aim for the second resistance level at HK$10.6. Conversely, if overbought pressure triggers a pullback, attention should focus on the defensive strength at the first support level of HK$9.26, which is close to the strong support areas of MA10 (HK$9.78)...
Faced with the contradiction between buy signals and overbought pressure, would you choose to chase gains with call warrants/bull contracts, or opt for bear contracts to hedge against adjustments? Would you add positions to chase gains or take profits when appropriate? Share your strategy in the comments!
This article is for reference only and does not constitute any investment advice. The market data, opinions, and analysis contained herein may change at any time without prior notice. We shall not be liable for any loss or damage arising from reliance on the information in this article. Technical analysis merely indicates whether certain technical conditions are met; a comprehensive evaluation of asset performance should incorporate additional data. Trading decisions should not be based solely on the content of this article. Please note that past performance is not indicative of future results.
#Stone Pharmaceutical #01093 #Innovative Drug #Warrant #Bull Bear Certificate #Technical Analysis #Support Level #Resistance Level #Hong Kong Stock Investment #Pharmaceutical Sector
Risk Disclaimer: The above content only represents the author's view. It does not represent any position or investment advice of Futu. Futu makes no representation or warranty.Read more
Thumbs Up
1
41K Views
Report
Comments
Write a Comment...
1